Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
Jürgen Behr(Ludwig-Maximilians-Universität München), Simone Hummler(Heidelberg University), Michael Kreuter(Johannes Gutenberg University Mainz), Nicolas Schönfeld(Helios Klinikum Emil von Behring), Nicolas Kahn(Heidelberg University), Antje Prasse(University Medical Center Freiburg), Matthias Held(Medical Mission Institute), Hubert Wirtz(Coral Reef Alliance), Klaus F. Rabe(Christian-Albrechts-Universität zu Kiel), Marion Frankenberger(Asklepios Fachkliniken München-Gauting), Francesco Bonella(Ruhrlandklinik), Wolfgang Neumeister(Katholisches Klinikum Koblenz), N Schönfeld(Helios Klinikum Emil von Behring), Nikolaus Kneidinger(German Center for Lung Research), Julia Freise(Medizinische Hochschule Hannover), Petra Neuser(Philipps University of Marburg), Dirk Koschel, Tobias Welte(Medizinische Hochschule Hannover), Martin Claussen(LungenClinic Grosshansdorf), Stefan Blaas, Silke Tello(Justus-Liebig-Universität Gießen), Peter Hammerl, Johannes Johow(German Center for Lung Research), R. Bonnet(Zentralklinik Bad Berka), Joachim H. Ficker(Paracelsus Medizinische Privatuniversität), Andreas Günther(Cardio-Pulmonary Institute), Heinrike Wilkens(Saarland University), Christian Grohé(DRK Kliniken Berlin)
Cited by 523
Related Papers
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Sarcoidosis
|The Lancet|2013|1.1k
Clinical and economic burden of community-acquired pneumonia among adults in Europe
|Thorax|2010|1.1k
Chronic Obstructive Pulmonary Disease Phenotypes: The Future of COPD
|American Journal of Respiratory and Critical Care Medicine|2010|1k